On Monday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) opened higher 4.53% from the last session, before settling in for the closing price of $18.11. Price fluctuations for NAMS have ranged from $14.06 to $27.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 32.30% at the time writing. With a float of $62.27 million, this company’s outstanding shares have now reached $112.17 million.
The firm has a total of 68 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -402.49%, and the pretax margin is -397.45%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of NewAmsterdam Pharma Company NV is 44.54%, while institutional ownership is 57.42%. The most recent insider transaction that took place on May 15 ’25, was worth 5,598,975. Before that another transaction happened on Apr 11 ’25, when Company’s Affiliate proposed sale 1,433,193 for $15.12, making the entire transaction worth $21,669,878.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.30% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Check out the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). In the past quarter, the stock posted a quick ratio of 19.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 45.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.92 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Analysing the last 5-days average volume posted by the [NewAmsterdam Pharma Company NV, NAMS], we can find that recorded value of 0.7 million was lower than the volume posted last year of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 51.46%. Additionally, its Average True Range was 1.12.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 38.51%, which indicates a significant decrease from 76.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.43% in the past 14 days, which was lower than the 56.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.47, while its 200-day Moving Average is $19.96.
